TY - JOUR
T1 - Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
AU - Mardinoglu, Adil
AU - Bjornson, Elias
AU - Zhang, Cheng
AU - Klevstig, Martina
AU - Söderlund, Sanni
AU - Ståhlman, Marcus
AU - Adiels, Martin
AU - Hakkarainen, Antti
AU - Lundbom, Nina
AU - Kilicarslan, Murat
AU - Hallström, Björn M.
AU - Lundbom, Jesper
AU - Vergès, Bruno
AU - Barrett, Peter Hugh R.
AU - Watts, Gerald F.
AU - Serlie, Mireille J.
AU - Nielsen, Jens
AU - Uhlén, Mathias
AU - Smith, Ulf
AU - Marschall, Hanns-Ulrich
AU - Taskinen, Marja-Riitta
AU - Boren, Jan
PY - 2017
Y1 - 2017
N2 - To elucidate the molecular mechanisms underlying non-alcoholic fatty liver disease (NAFLD), we recruited 86 subjects with varying degrees of hepatic steatosis (HS). We obtained experimental data on lipoprotein fluxes and used these individual measurements as personalized constraints of a hepatocyte genome-scale metabolic model to investigate metabolic differences in liver, taking into account its interactions with other tissues. Our systems level analysis predicted an altered demand for NAD(+) and glutathione (GSH) in subjects with high HS Our analysis and metabolomic measurements showed that plasma levels of glycine, serine, and associated metabolites are negatively correlated with HS, suggesting that these GSH metabolism precursors might be limiting. Quantification of the hepatic expression levels of the associated enzymes further pointed to altered de novo GSH synthesis. To assess the effect of GSH and NAD(+) repletion on the development of NAFLD, we added precursors for GSH and NAD(+) biosynthesis to the Western diet and demonstrated that supplementation prevents HS in mice. In a proof-of-concept human study, we found improved liver function and decreased HS after supplementation with serine (a precursor to glycine) and hereby propose a strategy for NAFLD treatment
AB - To elucidate the molecular mechanisms underlying non-alcoholic fatty liver disease (NAFLD), we recruited 86 subjects with varying degrees of hepatic steatosis (HS). We obtained experimental data on lipoprotein fluxes and used these individual measurements as personalized constraints of a hepatocyte genome-scale metabolic model to investigate metabolic differences in liver, taking into account its interactions with other tissues. Our systems level analysis predicted an altered demand for NAD(+) and glutathione (GSH) in subjects with high HS Our analysis and metabolomic measurements showed that plasma levels of glycine, serine, and associated metabolites are negatively correlated with HS, suggesting that these GSH metabolism precursors might be limiting. Quantification of the hepatic expression levels of the associated enzymes further pointed to altered de novo GSH synthesis. To assess the effect of GSH and NAD(+) repletion on the development of NAFLD, we added precursors for GSH and NAD(+) biosynthesis to the Western diet and demonstrated that supplementation prevents HS in mice. In a proof-of-concept human study, we found improved liver function and decreased HS after supplementation with serine (a precursor to glycine) and hereby propose a strategy for NAFLD treatment
U2 - https://doi.org/10.15252/msb.20167422
DO - https://doi.org/10.15252/msb.20167422
M3 - Article
C2 - 28254760
SN - 1744-4292
VL - 13
SP - 916
JO - Molecular systems biology
JF - Molecular systems biology
IS - 3
ER -